Tumor Site Articles & Analysis
9 articles found
In cancer research, engineered enzymes are being explored to activate prodrugs locally at the tumor site, minimizing systemic toxicity—a testament to the intersection of enzymology and drug delivery innovation. ...
PEG derivatives mitigate this issue by masking the immunogenic sites of proteins, making them less recognizable to the immune system. ...
Introduction Chemotherapy with anti-tumor agents is currently one of the most important systemic treatments for cancer. ...
In the field of medicine, effectively delivering drugs to the target site in the body is crucial for successful treatment. Over the years, several innovative drug delivery systems have been developed to improve drug efficacy and patient outcomes. ...
NIR-PIT drugs can form a new targeted anti-tumor platform that irradiates infrared light to the tumor site through the device. ...
At present, 15 ADCs have been approved globally for hematological malignancies and solid tumors. In addition, more than 100 ADC drug candidates are currently under clinical investigation. ...
Cytokines-mediated signaling is a primary way of immune system communication. The common gamma-chain family of cytokines is a set of six cytokines that signal through the common cytokine γ chain receptor (γc/CD132/IL2RG). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Besides the IL-2RG receptor subunit, the γc family cytokine receptors include IL-2RB ...
Treatment field and target In the field of treatment, the main research and development direction of ADC drugs is concentrated in the field of anti-tumor. There are few competitors in the rest of the treatment field, but there are many potential products. ...
With oncoplastic surgery, the lumpectomy site rarely correlates with the incisional scar and presence or absence of a seroma can no longer be counted on to correlate with the lumpectomy bed. ...